Targeting SARS-CoV-2 replication with the nucleoside analogue 4'-Fluorouridine

Read full text Summarise with VIRAT
Authors: Hannah Fuchs
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

The emergence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the resulting Coronavirus Disease 2019 (COVID-19) pandemic developed into a globally devastating event. This experience highlighted the urgent need to improve preparedness for future viral outbreaks, including the development of first-line broad-spectrum antiviral drugs. Such drugs must meet several criteria beyond broad antiviral efficacy, such as oral availability, low risk of resistance development, limited adverse effects, and suitability for stockpiling. The nucleoside analog 4’-fluorouridine (4’-FlU) has previously shown promising activity against a range of ribonucleic acid (RNA) viruses through its mechanism of delayed/immediate chain termination, suggesting its potential as a first-line antiviral. However, variability in antiviral potency across viruses encouraged the aim of this work: to enhance its efficacy. Because viruses depend on host-derived nucleosides for replication and transcription, inhibiting endogenous de novo nucleotide synthesis may increase the incorporation of antiviral nucleoside analogs. Indeed, combining 4’-FlU with inhibitors of dihydroorotate dehydrogenase (DHODH), a key enzyme in pyrimidine biosynthesis, yielded a synergistic antiviral effect. Multiple in vitro assays confirmed this synergy, supporting the further evaluation of this combination therapy for clinical use. As no data existed on SARS-CoV-2 resistance to 4’-FlU, this study also presents the in vitro selection of resistant mutants. Notably, treatment with 4’-FlU and DHODH inhibitors re sensitized these mutants, further supporting the therapeutic potential of this drug combination. Subsequent analysis of resistance-associated mutations identified several promising candidates for deeper investigation. Finally, 4’-FlU exhibited a strong antiviral effect even in 2-hour transient treatment, initiated prior to infection and distinguishing it from currently approved anti-SARS-CoV-2 drugs. These results indicate clinically favorable pharmacokinetic properties of 4’-FlU. In conclusion, 4’-FlU showed considerable potency against SARS-CoV-2, and its combination with an inhibitor of pyrimidine synthesis further enhanced its antiviral effect. This outlines a synergistic strategy to achieve therapeutic efficacy against SARS-CoV-2 and potentially a broader range of RNA viruses.

Fields of Study & Subjects

SARS-CoV-2 and COVID-19 Research Biochemical and Molecular Research COVID-19 Clinical Research Studies

Publication details

Journal / source
eDiss (Georg-August-Universität Göttingen)
Publication date
1 January 2026
Language
EN
Document type
Thesis